Medication for Diarrhea

Marion Debus

Last update: 12.06.2019

  • For diarrhea:
    Birkenkohle comp. caps. WELEDA (also available as Carbo Betulae comp. tabs. WELEDA), 2 per bowel movement, or 3 x daily up to hourly
    or
    Bolus alba comp. powder WALA, 1–3 tsp. daily, each in 200 ml liquid 

  • For diarrhea and vomiting:
    Bolus alba comp. powder WALA, 1 saltsp. (~1/4 tsp.) hourly 

  • In situations of damage to the small intestine mucosa caused by chemotherapy or radiation therapy:
    Digestodoron® WELEDA, chew 2 tabs. at the beginning of each meal 3x/d, or 15 drops 4x/d
    or
    in addition, to stimulate renal and hepatic detoxification function while undergoing chemotherapy:
    Aquilinum comp. pillules WALA, 7–10 pillules 3x/d or 1 amp. per os 1x/d

  • In case of mucous membrane damage as a result of radiation therapy:
    Stibium arsenicosum D6 trit. WELEDA, 1 saltsp. (~1/4 tsp.) 3x/d
    or,
    with particularly mucousy diarrhea:
    Geum urbanum D1 WELEDA, 10 drops 3–6x/d

  • For Enterocolitis with mucousy diarrhea and high fluid loss:
    Quartz powder 50% WELEDA, take ¼ tsp. with a little liquid 5x/d

  • For unrelenting diarrhea in GvHD after bone marrow transplantation:
    Luvos Healing Earth gastro balance (also available as Luvos-Heilerde magenfein), 1 tsp. 3x/d

  • Diarrhea during radiation of the rectum as part of (neo)adjuvant chemoradiotherapy for rectal cancer. In the last third of therapy, local irritations and diarrhea can usually be expected.
    Local: Mercurialis ointment WALA and Mercurialis comp. supp. WALA 
    or,
    Bolus alba comp. powder WALA
    Stibium arsenicosum D6 trit. WELEDA, 1 saltsp. (~1/4 tsp.) 3x/d
    Geum urbanum D1 WELEDA, 10 drops 3–6x/d

Research news

Mistletoe therapy in addition to standard immunotherapy in patients with non-small-cell lung cancer indicates improved survival rates 
Immunotherapy with PD-1/PD-L1 inhibitors has significantly improved the survival rates of patients with metastatic non-small-cell lung cancer (NSCLC). Results of a real-world data study (RWD) investigating the addition of Viscum album L. (VA) to chemotherapy have shown an association with improved survival in patients with NSCLC - regardless of age, degree of metastasis, performance status, lifestyle or oncological treatment. The mechanisms may include synergistic modulations of the immune response by PD-1/PD-L1 inhibitors and VA. However, the results should be taken with caution due to the observational and non-randomised study design. The study has been published open access in Cancers
https://doi.org/10.3390/cancers16081609.


Further information on Anthroposophic Medicine